Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia - PubMed (original) (raw)

Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia

Jia Liu et al. J Mol Cell Cardiol. 2006 Feb.

Abstract

Increased hexosamine biosynthesis pathway (HBP) flux and elevated levels of protein O-linked-N-acetylglucosamine (O-GlcNAc) decrease calcium influx into isolated cardiomyocytes. Increased O-GlcNAc levels also increase tolerance of cells to stress. Therefore, the goal of this study was to test the hypothesis that increasing HBP flux and protein O-GlcNAc levels in the intact heart will increase the tolerance to tissue injury resulting from the calcium paradox and ischemia. We used two strategies that have been shown to increase HBP flux in the intact heart, namely a brief period of streptozotocin-induced diabetes and acute pretreatment of the isolated perfused heart with glucosamine. Isolated perfused rat hearts were exposed to the calcium paradox or to ischemia and reperfusion. Both diabetes and glucosamine significantly improved recovery in the isolated perfused rat heart following the calcium paradox with left ventricular developed pressure (LVDP) returning to ~80% of baseline compared to 0% in controls (P<0.05), and lactate dehydrogenase release being reduced by approximately fivefold (P<0.05). In the diabetic group, azaserine, which inhibits the HBP, restored the sensitivity to the calcium paradox. Glucosamine treatment also improved functional recovery following ischemia/reperfusion (LVDP: 47+/-9% vs. 95+/-4%, P<0.05) and this was associated with a threefold increase in O-GlcNAc levels (P<0.05). Alloxan, an inhibitor of O-GlcNAc-transferase, blocked both the protection seen with glucosamine and the increase in O-GlcNAc. These data demonstrate that activation of the HBP with glucosamine may be a novel strategy for inducing cardioprotection, and that this appears to be mediated by an increase in protein O-GlcNAc levels.

PubMed Disclaimer

Cited by

Dynamic O-GlcNAcylation and its roles in the cellular stress response and homeostasis.
Groves JA, Lee A, Yildirir G, Zachara NE. Groves JA, et al. Cell Stress Chaperones. 2013 Sep;18(5):535-58. doi: 10.1007/s12192-013-0426-y. Epub 2013 Apr 26. Cell Stress Chaperones. 2013. PMID: 23620203 Free PMC article.
Discovery of a New Drug-like Series of OGT Inhibitors by Virtual Screening.
Loi EM, Tomašič T, Balsollier C, van Eekelen K, Weiss M, Gobec M, Alteen MG, Vocadlo DJ, Pieters RJ, Anderluh M. Loi EM, et al. Molecules. 2022 Mar 19;27(6):1996. doi: 10.3390/molecules27061996. Molecules. 2022. PMID: 35335358 Free PMC article.
O-GlcNAc modification of proteins affects volume regulation in Jurkat cells.
Nagy T, Balasa A, Frank D, Rab A, Rideg O, Kotek G, Magyarlaki T, Bogner P, Kovács GL, Miseta A. Nagy T, et al. Eur Biophys J. 2010 Jul;39(8):1207-17. doi: 10.1007/s00249-009-0573-3. Epub 2009 Dec 31. Eur Biophys J. 2010. PMID: 20043149
O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death.
Ngoh GA, Hamid T, Prabhu SD, Jones SP. Ngoh GA, et al. Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1711-9. doi: 10.1152/ajpheart.00553.2009. Epub 2009 Sep 4. Am J Physiol Heart Circ Physiol. 2009. PMID: 19734355 Free PMC article.
Acute increases in _O_-GlcNAc indirectly impair mitochondrial bioenergetics through dysregulation of LonP1-mediated mitochondrial protein complex turnover.
Wright JN, Benavides GA, Johnson MS, Wani W, Ouyang X, Zou L, Collins HE, Zhang J, Darley-Usmar V, Chatham JC. Wright JN, et al. Am J Physiol Cell Physiol. 2019 Jun 1;316(6):C862-C875. doi: 10.1152/ajpcell.00491.2018. Epub 2019 Mar 13. Am J Physiol Cell Physiol. 2019. PMID: 30865517 Free PMC article.

Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia - PubMed (original) (raw)